黑德拉沙尼C通过向TLR4来抑制NF-κB/MAPK信号通路来改善慢性阻塞性肺病的病原性
Yujie Ning1,2, Liting Huang1,2, Qin-Qin Wang1,2,3
1Engineering Research Center of Innovative Drugs for Traditional Chinese Medicine and Zhuang & Yao Medicine, Ministry of Education, Nanning, 530200, China.
Chinese medicine
|July 3, 2025
概括
黑德拉沙尼C (HSC) 通过向TLR4并减少炎症和粘液产生,有效治疗慢性阻塞性肺病 (COPD). 这种天然化合物在控制COPD症状和进展方面表现有前途.
科学领域:
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
- 分子生物学分子生物学
背景情况:
- 慢性阻塞性肺病 (COPD) 是一种由炎症和组织重塑驱动的渐进性呼吸道疾病.
- 暴露于污染物会激活NF-κB/MAPK通路,导致蛋白酶-抗蛋白酶失衡和过度的粘液分泌.
- 黑德拉沙宁C (HSC),一种沙宁,表现出抗炎功能,但其在COPD中的机制需要阐明.
研究的目的:
- 在慢性阻塞性肺病 (COPD) 的临床前模型中研究Hederasaponin C (HSC) 的治疗机制.
- 评估HSC对关键炎症信号通路,矩阵金属蛋白酶 (MMP) 和COPD中的粘素产生的影响.
- 在体内评估HSC在缓解COPD症状方面的有效性.
主要方法:
- 在体外研究中使用了西方抹杀,qRT-PCR和ELISA来分析NF-κB/MAPK信号,MMP9/MMP12和MUC-5AC/MUC-5B的表达.
- 用分子对接,SPR和CETSA来确定HSC与TLR4的结合亲和力.
- 在体内研究涉及COPD的老鼠模型由香烟烟雾和LPS诱导,通过组织学和分子分析进行评估.
主要成果:
- 通过向TLR4和减弱NF-κB/MAPK信号,HSC显著抑制了CSE+LPS诱导的炎症.
- HSC降低了MMP9,MMP12,MUC-5AC和MUC-5B的表达,并抑制了MUC-5B的DNA甲基化.
- 在体内,HSC减轻了小鼠的COPD症状,减少了TLR4/NF-κB/MAPK通路的激活.
结论:
- 通过向TLR4和调节NF-κB/MAPK信号通路,HSC证明了COPD的治疗潜力.
- 在COPD模型中,HSC减少炎症,恢复蛋白酶-抗蛋白酶平衡,并减轻粘液过分分泌.
- 这些发现支持HSC作为治疗慢性阻塞性肺病的有希望的治疗剂.
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.1K
Drugs Used in Lower Respiratory Disorders: Overview
618
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
618
Antiasthma Drugs: Leukotriene Modifiers
495
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
495
COPD: Pathogenesis and Clinical Features
535
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
535
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
227
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
227
Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K


